Cathie's Ark Logo
Exact Sciences Corp. Logo

ARKG Holdings of Exact Sciences Corp. (EXAS) - Updated Daily

Liquid BiopsyGenomicsGenetic Testing
Date
Direction
Shares
Fund Weight
Fund
September 6, 2023
SELL8.074k0.0325%ARKG
July 26, 2023
SELL10.000k0.0411%ARKG
July 25, 2023
SELL71.800k0.2933%ARKG
June 21, 2023
SELL10.960k0.048%ARKG
June 20, 2023
SELL14.856k0.0637%ARKG

Key Statistics

⚖️Weighting🧢Market Cap
9.66%$12.00b
🏋🏿‍♂️Weight Rank In ARKG🌏Country
1🇺🇸United States
🏋️‍♀️Weight Rank Across All Funds💳ARK Estimated Cost Average
7$94.56
🎫ARK Ownership Percent
1.39%
Description
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences'​ noninvasive colon cancer screening test, visit cologuardtest.com
Website
https://www.exactsciences.com/

Other ETFs That Hold EXAS

Ticker
NameWeight
ARKGARK Genomic Revolution ETF11.77%
ARKKARK Innovation ETF6.43%
XBISPDR® S&P Biotech ETF1.49%
AGNGGlobal X Aging Population ETF0.85%
LABUS&P Biotech Bull 3X Shares ETF0.209%

Research Notes and Commentary for EXAS

No Research Notes Found for EXAS